Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1997 Dec;81(12):1107–1112. doi: 10.1136/bjo.81.12.1107

Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A

A Dick 1, M Azim 1, J Forrester 1
PMCID: PMC1722078  PMID: 9497474

Full Text

The Full Text of this article is available as a PDF (126.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Recovery of visual acuity in a cohort of patients with EPU treated with a reducing course of prednisolone and maintenance of less than 10 mg/day of prednisolone. All affected eyes are included in plot. In general there is visual recovery or vision is protected. 36/53 eyes showed improvement in vision or maintained visual acuity (20 eyes and 16 eyes respectively) and only 6/53 eyes suffered a visual loss of greater than 2 lines of Snellen vision.

Figure 2  .

Figure 2  

Open in a new tab

Recovery of visual acuity in a cohort of patients with EPU treated with combined low dose CsA (<5 mg/kg/day) and prednisolone (<10 mg/day). All affected eyes are included in plot. The vision of 21/54 eyes improved with this therapy, and a further 20/54 eyes maintained their presenting vision. 10/54 eyes still had a visual acuity loss of greater than 2 lines of Snellen vision.

Figure 3  .

Figure 3  

Open in a new tab

Recovery of visual acuity in a cohort of patients with EPU treated with combined low dose CsA (<5 mg/kg/day) and azathioprine (1-3 mg/kg/day) and variable maintenance doses of oral prednisolone. All affected eyes are included in plot. The inflammation in 14/24 eyes was able to be controlled so that the vision either improved (4/24) or was maintained (10/24). However, the vision in 10/24 eyes did deteriorate despite triple therapy.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arocker-Mettinger E., Steurer-Georgiew L., Steurer M., Huber-Spitzy V., Hoelzl E., Grabner G., Kuchar A. Circulating ICAM-1 levels in serum of uveitis patients. Curr Eye Res. 1992;11 (Suppl):161–166. doi: 10.3109/02713689208999527. [DOI] [PubMed] [Google Scholar]
  2. Calne R. Y. Immunosuppression for organ grafting -- observations on cyclosporin A. Immunol Rev. 1979;46:113–124. doi: 10.1111/j.1600-065x.1979.tb00286.x. [DOI] [PubMed] [Google Scholar]
  3. Caspi R. R., Roberge F. G., McAllister C. G., el-Saied M., Kuwabara T., Gery I., Hanna E., Nussenblatt R. B. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986 Feb 1;136(3):928–933. [PubMed] [Google Scholar]
  4. Chanaud N. P., 3rd, Vistica B. P., Eugui E., Nussenblatt R. B., Allison A. C., Gery I. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res. 1995 Oct;61(4):429–434. doi: 10.1016/s0014-4835(05)80138-1. [DOI] [PubMed] [Google Scholar]
  5. Chisholm I. H., Gass J. D., Hutton W. L. The late stage of serpiginous (geographic) choroiditis. Am J Ophthalmol. 1976 Sep;82(3):343–351. doi: 10.1016/0002-9394(76)90482-7. [DOI] [PubMed] [Google Scholar]
  6. Dick A. D., Cheng Y. F., Purdie A. T., Liversidge J., Forrester J. V. Immunocytochemical analysis of blood lymphocytes in uveitis. Eye (Lond) 1992;6(Pt 6):643–647. doi: 10.1038/eye.1992.138. [DOI] [PubMed] [Google Scholar]
  7. Dick A. D. Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol. 1995 Jan;79(1):81–88. doi: 10.1136/bjo.79.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dick A. D., Towler H. M., Whiting P., Forrester J. V. The use of lithium clearance studies in the early detection of cyclosporin A (CsA) nephrotoxicity: a protocol of renal function assessment with CsA therapy. Curr Eye Res. 1992;11 (Suppl):215–218. doi: 10.3109/02713689208999536. [DOI] [PubMed] [Google Scholar]
  9. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  10. Forrester J. V. Duke-Elder Lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye (Lond) 1992;6(Pt 5):433–446. doi: 10.1038/eye.1992.93. [DOI] [PubMed] [Google Scholar]
  11. Forrester J. V. Endogenous posterior uveitis. Br J Ophthalmol. 1990 Oct;74(10):620–623. doi: 10.1136/bjo.74.10.620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Forrester J. V., Liversidge J., Dua H. S., Towler H., McMenamin P. G. Comparison of clinical and experimental uveitis. Curr Eye Res. 1990;9 (Suppl):75–84. doi: 10.3109/02713689008999424. [DOI] [PubMed] [Google Scholar]
  13. GORDON D. M. Prednisone and prednisolone in ocular disease. Am J Ophthalmol. 1956 Apr;41(4):593–600. [PubMed] [Google Scholar]
  14. Granelli-Piperno A. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med. 1988 Nov 1;168(5):1649–1658. doi: 10.1084/jem.168.5.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Helm C. J., Holland G. N. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995 Jul;120(1):55–64. doi: 10.1016/s0002-9394(14)73759-6. [DOI] [PubMed] [Google Scholar]
  16. Hooper P. L., Kaplan H. J. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991 Jun;98(6):944–952. doi: 10.1016/s0161-6420(91)32198-5. [DOI] [PubMed] [Google Scholar]
  17. Howe L. J., Stanford M. R., Edelsten C., Graham E. M. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye (Lond) 1994;8(Pt 4):443–447. doi: 10.1038/eye.1994.105. [DOI] [PubMed] [Google Scholar]
  18. Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748–752. doi: 10.1016/0140-6736(92)92294-p. [DOI] [PubMed] [Google Scholar]
  19. Isaacs J., Dick A. Short term immunosuppressive therapy and long-term immunoregulation: promises and problems. Br J Ophthalmol. 1996 Dec;80(12):1035–1036. doi: 10.1136/bjo.80.12.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ishioka M., Ohno S., Nakamura S., Isobe K., Watanabe N., Ishigatsubo Y., Tanaka S. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994 Dec 15;118(6):723–729. doi: 10.1016/s0002-9394(14)72551-6. [DOI] [PubMed] [Google Scholar]
  21. Jennings T., Rusin M. M., Tessler H. H., Cunha-Vaz J. G. Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol. 1988;32(4):385–391. [PubMed] [Google Scholar]
  22. Lightman S. Use of steroids and immunosuppressive drugs in the management of posterior uveitis. Eye (Lond) 1991;5(Pt 3):294–298. doi: 10.1038/eye.1991.46. [DOI] [PubMed] [Google Scholar]
  23. Lightman S. Uveitis: management. Lancet. 1991 Dec 14;338(8781):1501–1504. doi: 10.1016/0140-6736(91)92310-x. [DOI] [PubMed] [Google Scholar]
  24. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today. 1993 Jun;14(6):290–295. doi: 10.1016/0167-5699(93)90048-P. [DOI] [PubMed] [Google Scholar]
  25. Nussenblatt R. B., Gery I., Weiner H. L., Ferris F. L., Shiloach J., Remaley N., Perry C., Caspi R. R., Hafler D. A., Foster C. S. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997 May;123(5):583–592. doi: 10.1016/s0002-9394(14)71070-0. [DOI] [PubMed] [Google Scholar]
  26. Nussenblatt R. B., Palestine A. G., Chan C. C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep;96(3):275–282. doi: 10.1016/s0002-9394(14)77814-6. [DOI] [PubMed] [Google Scholar]
  27. Nussenblatt R. B., Palestine A. G., Chan C. C., Stevens G., Jr, Mellow S. D., Green S. B. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991 Aug 15;112(2):138–146. doi: 10.1016/s0002-9394(14)76692-9. [DOI] [PubMed] [Google Scholar]
  28. Nussenblatt R. B., Rodrigues M. M., Wacker W. B., Cevario S. J., Salinas-Carmona M. C., Gery I. Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest. 1981 Apr;67(4):1228–1231. doi: 10.1172/JCI110138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Palestine A. G., Muellenberg-Coulombre C. G., Kim M. K., Gelato M. C., Nussenblatt R. B. Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest. 1987 Apr;79(4):1078–1081. doi: 10.1172/JCI112921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Palestine A. G., Nussenblatt R. B., Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc. 1988 Jun;20(3 Suppl 4):131–135. [PubMed] [Google Scholar]
  31. Pascalis L., Pia G., Aresu G., Frongia T., Barca L. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun. 1993 Aug;6(4):467–480. doi: 10.1006/jaut.1993.1039. [DOI] [PubMed] [Google Scholar]
  32. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum. 1996 Nov;39(11):1791–1801. doi: 10.1002/art.1780391104. [DOI] [PubMed] [Google Scholar]
  33. Rosenbaum J. T. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 1994 Jan;21(1):123–125. [PubMed] [Google Scholar]
  34. Rothova A. Ocular involvement in toxoplasmosis. Br J Ophthalmol. 1993 Jun;77(6):371–377. doi: 10.1136/bjo.77.6.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rothova A., Suttorp-van Schulten M. S., Frits Treffers W., Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332–336. doi: 10.1136/bjo.80.4.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Shah S. S., Lowder C. Y., Schmitt M. A., Wilke W. S., Kosmorsky G. S., Meisler D. M. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992 Sep;99(9):1419–1423. doi: 10.1016/s0161-6420(92)31790-7. [DOI] [PubMed] [Google Scholar]
  37. Suttorp-Schulten M. S., Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996 Sep;80(9):844–848. doi: 10.1136/bjo.80.9.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tabbara K. F. Chlorambucil in Behçet's disease. A reappraisal. Ophthalmology. 1983 Aug;90(8):906–908. doi: 10.1016/s0161-6420(83)80014-1. [DOI] [PubMed] [Google Scholar]
  39. Towler H. M., Cliffe A. M., Whiting P. H., Forrester J. V. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye (Lond) 1989;3(Pt 3):282–287. doi: 10.1038/eye.1989.39. [DOI] [PubMed] [Google Scholar]
  40. Towler H. M., Lightman S. L., Forrester J. V. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun. 1992 Apr;5 (Suppl A):259–264. doi: 10.1016/0896-8411(92)90041-n. [DOI] [PubMed] [Google Scholar]
  41. Towler H. M., Whiting P. H., Forrester J. V. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye (Lond) 1990;4(Pt 3):514–520. doi: 10.1038/eye.1990.68. [DOI] [PubMed] [Google Scholar]
  42. Waldmann H., Cobbold S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol Today. 1993 Jun;14(6):247–251. doi: 10.1016/0167-5699(93)90040-R. [DOI] [PubMed] [Google Scholar]
  43. Walsh L. J., Wong C. A., Pringle M., Tattersfield A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996 Aug 10;313(7053):344–346. doi: 10.1136/bmj.313.7053.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Weijtens O., van der Sluijs F. A., Schoemaker R. C., Lentjes E. G., Cohen A. F., Romijn F. P., van Meurs J. C. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997 Mar;123(3):358–363. doi: 10.1016/s0002-9394(14)70131-x. [DOI] [PubMed] [Google Scholar]
  45. Whitcup S. M., Salvo E. C., Jr, Nussenblatt R. B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol. 1994 Jul 15;118(1):39–45. doi: 10.1016/s0002-9394(14)72840-5. [DOI] [PubMed] [Google Scholar]
  46. Yazici H., Pazarli H., Barnes C. G., Tüzün Y., Ozyazgan Y., Silman A., Serdaroğlu S., Oğuz V., Yurdakul S., Lovatt G. E. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990 Feb 1;322(5):281–285. doi: 10.1056/NEJM199002013220501. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES